Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 2 de 2
Filtre
Ajouter des filtres








Gamme d'année
1.
The Korean Journal of Internal Medicine ; : 128-131, 2004.
Article Dans Anglais | WPRIM | ID: wpr-122271

Résumé

Gallbladder perforation is an almost exclusive complication of cholecystitis, which accompanies severe inflammation of the gallbladder with or without cholelithiasis. Whether it is of a calculous or acalculous origin, gallbladder perforation, as a complication of acute cholecystitis, has common symptoms, signs, laboratory data, radiological findings and treatment modalities. Even though many reports of gallbladder perforation have been published, there are few reports of gallbladder perforation without any clinical and radiological indications. We experienced a case of a 70-year-old woman with acute abdomen, which was found to be peritonitis caused by spontaneous gallbladder perforation that was devoid of clues suggesting this condition. Although rare and unusual, this case shows that this disorder should be considered in elderly patients presenting with peritonitis with an unknown etiology.


Sujets)
Sujet âgé , Femelle , Humains , Maladies de la vésicule biliaire/complications , Péritonite/diagnostic , Tomodensitométrie , Échographie interventionnelle
2.
The Korean Journal of Gastroenterology ; : 468-475, 2003.
Article Dans Anglais | WPRIM | ID: wpr-96877

Résumé

BACKGROUND/AIMS: Genetic polymorphism of cytochrome P450 CYP2C19 influences the efficacy of proton pump inhibitor (PPI) in Helicobacter pylori (H. pylori) eradication therapy. We investigated the difference in the cure rates of H. pylori infection by triple (rabeprazole plus amoxacillin and clarithromycin) therapy in relation to CYP2C19 genotype status. METHODS: One hundred and sixteen H. pylori infected patients with gastric ulcer and duodenal ulcer completed the triple therapy with 10 mg of rabeprazole b.i.d., 1,000 mg amoxacillin b.i.d. and 500 mg of clarithromycin b.i.d. for one week. The genotype of CYP2C19 was determined by a PCR-restriction fragment length polymorphism method. RESULTS: According to the univariate analysis, heterozygous extensive metabolizers (hetero EMs) and poor metabolizers (PMs) showed the highest (87.0%) and the lowest (80.0%) eradication rates, respectively. The difference in the therapeutic efficacy of rabeprazole among the different CYP2C19 genotypes was insignificant. With regard to gender, age and smoking history in relation to eradication rate, a statistical significance was noted only with age with odds ratio of 1.063 and p-value of 0.0202. CONCLUSIONS: In the eradication therapy of H. pylori, no statistically significant difference in therapeutic efficacy of rabeprazole was found among different CYP2C19 genotypes.


Sujets)
Adulte , Sujet âgé , Femelle , Humains , Mâle , Adulte d'âge moyen , (Pyridin-2-ylméthyl)sulfinyl-1H-benzimidazoles , Amoxicilline/administration et posologie , Antibactériens/administration et posologie , Antiulcéreux/administration et posologie , Aryl hydrocarbon hydroxylases/génétique , Benzimidazoles/administration et posologie , Clarithromycine/administration et posologie , Association de médicaments , Ulcère duodénal/traitement médicamenteux , Génotype , Infections à Helicobacter/traitement médicamenteux , Helicobacter pylori , Mixed function oxygenases/génétique , Oméprazole/analogues et dérivés , Pompes à protons/antagonistes et inhibiteurs , Ulcère gastrique/traitement médicamenteux
SÉLECTION CITATIONS
Détails de la recherche